{"task_id": "3fd40cfaf3a37fda", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 213/464)", "text": "IOLOGY (CONT\u2019D)\n202\nGastrointestinal Stromal Tumor\n\n--- Page 224 ---\nCLINICAL FEATURES\nLOCOREGIONAL\nGI\nbleed,\nabdominal\nmass,\nabdominal pain\nMETASTATIC\nRUQ pain, jaundice\nCONSTITUTIONAL\nweight loss, anorexia, fatigue,\nhypoglycemia from secretion of IGFII (rare)\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, AST, ALT, ALP, bilir\nubin, INR, PTT, albumin\n\u0002\nIMAGING\nCT abd/pelvis \u0006 MRI, U/S abd, chest\nimaging, PET/CT in selected patients\n\u0002\nBIOPSY\nendoscopy, laparotomy. Consider KIT\nand PDGRA mutational testing for KIT negative\ntumors\nPROGNOSTIC ISSUES\nADVERSE PROGNOSTIC FACTORS\nsize, mitotic\nrate, tumor site (small intestine worse), incomplete\nresection (<35% vs. 50 65% 5 year survival)\nPREDICTIVE FACTORS\nexon 11 KIT mutation is\npredictive of response to imatinib compared to\nexon 9 KIT mutation or wild type\nMANAGEMENT\nRESECTABLE DISEASE\nsegmental resection without\nregional lymphadenectomy. Adjuvant imatinib 400 mg\nPO daily is recommended for at least 12 months for\npatients with intermediate to high risk GIST\nUNRESECTABLE, RECURRENT, OR METASTATIC\nDISEASE\nimatinib 400 mg/day (until disease\nprogression) is recommended, except for exon 9\nmutation in which imatinib 800 mg/day is appro\npriate.\nFor\npatients\nwith\nnon metastatic\nbut\nunresectable disease, consider neoadjuvant ima\ntinib\nfollowed\nby\nresection\nif\npossible.\nFor\npatients with potentially resectable metastatic\nGIST, surgery should be offered to those with\nstable disease, responding to tyrosine kinase\ninhibitor therapy, or with focal progression only.\nHepatic chemoembolization could be considered\nin isolated unresectable liver metastases. If pro\ngression on imatinib, increase dose to 800 mg/\nday. With further disease progression, sunitinib\nshould be considered\nAnal Cancer\nPATHOPHYSIOLOGY\nCLASSIFICATION BY HISTOLOGY (WHO)\n\u0002\nANAL CANAL\n\u0002\nSQUAMOUS CELL CARCINOMA (75%)\nlarge cell\nkeratinizing (distal to the dentate line) or non\nkeratinizing (above the dentate line).\n\u0002\nADENOCARCINOMA (20%)\nrectal type, of anal\nglands, within anorectal fistula\n\u0002\nSMALL CELL CARCINOMA\n\u0002\nUNDIFFERENTIATED\n\u0002\nANAL MARGIN (PERIANAL SKIN)\n\u0002\nSQUAMOUS CELL CARCINOMA\n\u0002\nGIANT CONDYLOMA\n\u0002\nBASAL CELL CARCINOMA\n\u0002\nOTHERS\nBowen\u2019s disease, Paget disease\nRISK FACTORS\n\u0002\nPERSONAL\nsexual activity (HPV, number of sexual\npartners, receptive anal intercourse, history of STD,\ngenital warts)\n\u0002\nENVIRONMENTAL\nsmoking\n\u0002\nDISEASES\nHIV and other causes of chronic immu\nnosuppression (e.g. solid organ transplantation).\nLYMPHATIC DRAINAGE\n\u0002\nTUMORS ORIGINATING ABOVE THE DENTATE LINE\ndrain to the perirectal and paravertebral LN\nPATHOPHYSIOLOGY (CONT\u2019D)\n\u0002\nTUMORS ORIGINATING BELOW THE DENTATE LINE\ndrain to the inguinal and femoral LN\nCLINICAL FEATURES\nLOCOREGIONAL\nrectal bleeding (45%), anal pain,\nand sensation of rectal mass (30%). Squamous cell\ncarcinoma may be associated with a history of anor\nectal condyloma (50%), while tumor of perianal skin\ncan be associated with pruritus ani\nMETASTATIC\nRUQ pain, dyspnea\nCONSTITUTIONAL\nweight loss, anorexia, fatigue\nSTAGING\nTNM STAGING\nT stage\n\u0002 T1 \u00042 cm\n\u0002 T2 >2 cm but \u00045 cm\n\u0002 T3 >5 cm\n\u0002 T4=invades adjacent organ(s) (involvement of\nsphincter muscle(s) alone is not classified as T4)\nN stage\n\u0002 N1=perirectal LN\n\u0002 N2=unilateral internal iliac LN and/or inguinal LN\n\u0002 N3=perirectal and inguinal LN and/or bilateral\ninternal iliac and/or inguinal lymph nodes\nAnal Cancer\n203", "text_length": 3355, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 213/464)", "type": "chunk", "chunk_index": 212, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.539543", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.540283", "status": "complete", "chunks_added": 2}